저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:

저작자표시. 귀하는 원저작자를 표시하여야 합니다.
비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.
변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 이용허락규약(Legal Code)를 이해하기 쉽게 요약한 것입니다.

Disclaimer
Prognostic role of survivin in bladder cancer

- a systematic review and meta-analysis -
방광암에서 survivin의
예후적 가치
- 체계적 문헌고찰과 메타 분석 -

Prognostic role of survivin in bladder cancer
- a systematic review and meta-analysis -

지도교수 구자현
이 논문을 의학석사 학위논문으로 제출함

2014년 10월

서울대학교 대학원
의학과 비뇨기과학 전공
전 찬 후
Prognostic role of survivin in bladder cancer: a systematic review and meta-analysis
ABSTRACT

Prognostic role of survivin in bladder cancer: systematic review and meta-analysis

Chanhoo Jeon
Student Number: 2013-21699
Urology, Department of Medicine, Seoul national university

Objective: The objective of the present study was to conduct a systematic review and meta-analysis of published literature investigating the survivin expression and its effects on bladder cancer prognosis.

Materials & Methods: We carefully searched online Pubmed, Cochrane Library and SCOPUS database from August 1997 to May 2013.

Results: A total of 14 articles met the eligibility criteria for this systematic review. The eligible studies included a total of 2,165 patients with a median number of 155 patients per study (range: 17-726). Of the 14 studies, nine evaluated immunohistochemistry in formalin-fixed paraffin-embedded tissue blocks. In non-muscle invasive bladder tumor, the pooled hazard ratio (HR) was statistically significant for recurrence-free survival (pooled HR, 1.81; 95% confidence interval [CI], 1.30-2.52), progression-free survival (pooled HR, 2.12; 95% CI, 1.60-2.82), cancer-specific survival (pooled HR, 2.01; 95% CI, 1.32-3.06), and overall survival (pooled HR, 1.53; 95% CI, 1.02-2.29). These estimates of the overall HRs by survivin status
were robust across advanced stages. When only adjusted survival data were included, statistically significant differences were identified for all survival subgroup analyses. There was no between-study heterogeneity in the effect of survivin status on the majority of meta-analyses. There was no clear evidence of publication bias in this meta-analysis.

**Conclusion:** Our meta-analysis has yielded significant association between survivin expression and bladder cancer prognosis. However, it is rather necessary that better designed studies need to provide a better conclusion about the relationship between survivin expression and the outcome of patients with bladder cancer.

---

**Keywords:** Bladder cancer, survivin, meta-analysis, prognosis
CONTENTS

Abstract ................................................................................................. i
Contents ................................................................................................. iii
List of tables .......................................................................................... iv
List of figures ............................................................................................ v
List of appendices ...................................................................................... vi

I. Introduction ......................................................................................... 1

II. Materials and Methods ...................................................................... 3
  1. Search strategy and selection criteria .............................................. 3
  2. Data extraction and quality assessments ......................................... 4
  3. Statistical analysis ........................................................................... 5

III. Results .............................................................................................. 8

IV. Discussion ........................................................................................ 12

V. Conclusions ....................................................................................... 17

References ............................................................................................. 18

Abstract in Korean ................................................................................. 41
List of tables

Table 1. Main characteristics of the eligible studies included in this meta-analysis ......................................................... 26

Table 2. Estimation of the hazard ratio of included studies .............. 27

Table 3. Summary of subgroup analysis in non-muscle invasive bladder tumor ................................................................. 28

Table 4. Summary of sensitivity analysis in non-muscle invasive bladder tumor ................................................................. 29

Table S1. Patient characteristics of included studies ....................... 30

Table S2. Tumor characteristics of included studies ....................... 31

Table S3. Survivin expression according to pathological features of included ................................................................. 32
List of figures

**Fig. 1.** Methodological flow chart of the systematic review .................. 33

**Fig. 2.** Forest plots of hazard ratios with random effects model for survivin in patients with non-muscle invasive bladder tumor. (A) Recurrence-free survival. (B) Progression-free survival. (C) Cancer-specific survival. (D) Overall survival. 34

**Fig. 3.** Funnel graphs of the assessment of potential publication bias in studies of survivin expression in patients with non-muscle invasive bladder tumor. (A) Recurrence-free survival. (B) Progression-free survival. (C) Cancer-specific survival. (D) Overall survival. 35

**Fig. 4.** Forest plots of hazard ratios with random effects model for survivin in patients with muscle invasive bladder tumor. (A) Recurrence-free survival. (B) Cancer-specific survival. 36

**Fig. 5.** Forest plots of hazard ratios with random effects model for surviving in patients with advanced or metastatic bladder tumor (overall survival) 36
List of appendices

Appendix 1. Patient characteristics of included studies .....................37

Appendix 2. Tumor characteristics of included studies ..................... 38

Appendix 3. Survivin expression according to pathological features of included studies .................................................................39

Appendix 4. Forest plots of hazard ratios with random effects model for survivin in patients with muscle invasive bladder tumor. (A) Recurrence-free survival. (B) Cancer-specific survival. ....40

Appendix 5. Forest plots of hazard ratios with random effects model for survivin in patients with advanced or metastatic bladder tumor (overall survival) .................................................................40
I. Introduction

Bladder cancer is the second most common cancer arising in the genitourinary tract [1], and is characterized by its variable prognosis. In about 70% of patients with non-muscle invasive bladder cancer, tumors recur and some of these patients will eventually show progression towards muscle invasive cancer. Tumors that are muscle invasive have a high risk of progression, despite radical cystectomy and other treatments. One of important focuses in bladder cancer research is the prediction of tumor recurrence and tumor progression. Conventional prognostic factors, like tumor stage and grade, do not accurately predict the clinical outcome of many patients with bladder cancer, because of the inherent heterogeneity of tumor biology and patient characteristics. Additional effective biomarkers are required for explaining variability of outcome in patients with bladder cancer.

The ability of molecular markers to predict recurrence and progression of the disease, response to treatment, and survival has been investigated intensively over the last decades. Although numerous potential bladder tumor markers have been identified, their significance remains controversial. Survivin has been recently described as the smallest, structurally unique member of the 'inhibitor of apoptosis' family [2]. As compared with normal differentiated adult tissues, survivin is frequently overexpressed in tumors [3]. Functionally, survivin displays regulatory functions for control of cell
division and inhibition of apoptosis, induces angiogenesis, and plays a pivotal role in cancer progression [4]. Because of this upregulation in malignancy and its functional involvement in apoptosis, as well as proliferation, survivin is attracting considerable interest as a potential cancer biomarker [5]. Generally, high survivin mRNA or protein expression is correlated with aggressive behavior of tumor cells, and survivin expression has been established as a prognostic factor in several tumor types [6-8].

Thus, in urothelial carcinoma of the urinary bladder, survivin has been suggested as a promising biomarker for cancer prognosis. Survivin expression has been reported to be indicator of poor prognosis in bladder cancer, whereas some other studies did not show the same results. Because reports about its prognostic significance in bladder cancer are comparatively few, the combination of these data to reach a reasonable conclusion is fairly necessary at present. The objective of the present study was to conduct a systematic review and meta-analysis of published literature investigating the survivin expression and its effects on bladder cancer prognosis. We also aimed to assess the quality of published studies.
II. Materials and Methods

1. Search strategy and selection criteria

We carefully searched online Pubmed, Cochrane Library and SCOPUS database. Since the first survivin article was published in 1997, we searched literatures published from August 1997 to May 2013, to identify relevant studies by combining the keywords [survivin] AND [urinary bladder neoplasms] OR [urinary AND bladder AND neoplasms] OR [bladder AND cancer] OR [bladder cancer]. To be eligible for our meta-analysis, studies had to be English-language published documents dealing with histopathologically confirmed bladder cancer at the time of study inclusion.

The inclusion criteria for our systematic review were, as follows: (i) articles were published in English in the periodical literature; (ii) the histologic type of the tumors was urothelial carcinoma; (iii) expression of the survivin was evaluated in tissues or urines; (iv) the association between survivin expression levels and survival outcome was investigated; and (v) the authors offered the size of the sample, hazard ratios (HRs) and their 95% confidence intervals (CIs) or other information that could help infer the survival results in the paper. When multiple articles were published by the same authors or group, the most recently published or most informative single article was selected to avoid duplication of the patient data. Duplicate reports were included in the specific analyses only if they performed
different subgroup analyses. No attempt was made to restrict the search according to more specific methodological characteristics. Accordingly, the following exclusion criteria were used: (i) review articles or letters to the editor; (ii) laboratory studies, such as studies on bladder cancer cell lines and animal models; and (iii) studies which did not provide sufficient data to acquire HR and its standard error.

To minimize the bias and to improve reliability, two independent reviewers (C.J. and J.H.K.) assessed the eligibility of abstracts identified by the search. If studies seemed appropriate, the full manuscript was scrutinized and the study was deemed “relevant” if it met the inclusion criteria. If the eligibility was unclear from the abstract, the full article was retrieved for clarification. The full text publication was independently screened by two of the authors (C.J. and J.H.K.). Disagreements between reviewers were resolved by consensus.

2. Data extraction and quality assessments

The extracted data elements of this review included the following: (i) publication details: country, first author's last name, publication year, period of recruitment, and study design; (ii) characteristics of the studied population: sample size, mean or median age, gender, inclusion and exclusion criteria, tumor characteristics, treatment, endpoint definition, and follow-up period; (iii) cut-off value of positive expression and the antibodies used for immunohistochemistry (IHC), as well as biologic samples and the type of measurements used to determine survivin status; and (iv) survival
curves, the exact data of total and exposed number in case and control groups, as well as HRs and their CIs.

Study quality was assessed independently by two investigators (C.J. and J.H.K.). Any disagreement was resolved by discussion. Although no standard quality assessment method is currently available, an assessment of study methodology was made according to previously defined criteria. We systematically assessed the quality of all included studies using the predefined form by De Graeff et al [9], which was adapted from Hayes et al [10] and McShane et al [11]. Briefly, the following criteria were investigated: (i) the study reported inclusion and exclusion criteria; (ii) study data were prospectively or retrospectively gathered; (iii) clinical and pathological characteristics of the patients were sufficiently described; (iv) the assay used was sufficiently described; (v) a definition of the study endpoint was provided; (vi) the follow-up time was described; and (vii) the study reported how many patients were lost to follow-up or were not available for statistical analysis.

3. Statistical analysis

Primary analysis. The recommended summary statistics for meta-analysis of time-to-event data are the logHR and its variance, which account for both the time it takes for an event to occur, as well as censoring. For each trial, this HR was estimated by a method depending on the data provided in the publications. The simplest method consisted in the direct collection of HR and their 95% CI from the original article. If those data
were not available, previously reported indirect methods were utilized for extracting the logHR and variance, due to the paucity of prognostic literature directly reporting these values [12-14]. A random-effect model was used to obtain the summary HRs and 95% CIs. An observed HR >1 indicated worse outcome for the study group relative to the reference group, and would be considered statistically significant if the 95% CI did not overlap, with p <0.05.

**Subgroup analysis.** Subsequently, we assessed the effect of unadjusted HR on the survivin results in patients with non-muscle invasive bladder tumor. First, attempt was made to use only adjusted survival data as part of this meta-analysis. Studies that did not report an adjusted HR for survival after controlling for potential confounding clinical variables in a multivariable analysis (e.g. Cox regression analysis including important clinical factors, such as age, grade, and/or performance status) were excluded, since the accuracy of HRs estimated from Kaplan-Meier survival curves without a multivariate analysis was uncertain [15-17]. These data were applied in a subgroup, and meta-analyses were performed to test the stability of our conclusions.

**Sensitivity analysis.** We performed sensitivity analyses in patients with non-muscle invasive bladder tumor. Through sensitivity analyses, we examined if our pooled estimate of the prognostic value of survivin status was largely influenced by the method for determination of survivin expression. Studies using immunohistochemical (IHC) expression were included in sensitivity analyses.
Assessment of heterogeneity. Heterogeneity was assessed using the chi-square test for heterogeneity, with a p value of <0.05 taken to reflect the presence of significant heterogeneity [18]. The $I^2$ statistic was calculated to quantify the degree of heterogeneity [19]. $I^2$ describes the proportion of total variation in meta-analysis estimates, which is due to inter-study heterogeneity, rather than sampling error, and is measured from 0% to 100%, with increasing $I^2$ values indicating a larger effect of between-study heterogeneity in the meta-analysis.

Publication bias. For those meta-analyses including 10 or more studies, we assessed the possibility of publication bias. Publication bias was evaluated using the funnel plot. In the absence of bias, the graph should resemble a symmetrical inverted funnel; conversely, in the presence of bias, the plot should appear skewed and asymmetrical.

The meta-analysis was undertaken using Review Manager (RevMan) software version 5.0 (RevMan 5; The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark).
Our search strategy identified 463 articles. Following deduplication, two reviewers independently screened the identified titles and abstracts. They subsequently agreed that 44 articles should be retrieved for detailed review; for these manuscripts, full texts were obtained. On careful review of study methodologies, 31 were excluded for the following reasons: 20 studies had no formal investigation of outcomes [20-39]. Instead, these studies assessed only the predictive ability and included the detection validity in the diagnosis of bladder cancer or based their results on association tests; seven studies provided incomplete information for HRs and 95% CIs [40-46]; and three studies were excluded because it contained duplicate data [47-49]. Thus, a total of 14 articles met the eligibility criteria for this systematic review [50-63]. A flow diagram of the study selection process is presented in Fig. 1.

Table 1 outlines the main characteristics of the included studies. Considering the selected studies, one was carried out in the United States, nine in Europe, three in Asia, and one was multinational. None of selected studies was prospective study. Patient tissues were the mostly common samples used to detect survivin, but in two studies [53,56] the authors used urine specimens to assess survivin mRNA. Of the 14 studies, nine evaluated IHC staining in formalin-fixed paraffin-embedded tissue blocks [52,54,55,57,58,60-63]. Tissue microarrays were created by using 0.6-mm
diameter cores from representative tissue region in one study [63], whereas two studies provided no core size details [55,62]. In the remaining studies, IHC was carried out on individual whole-slide tissue sections [52,54,57,58,60,61]. Four of nine (44.4%) did not define the primary antibody used [54, 55,61,62]. A wide range of dilutions was used (1/50 to 1/1,600). The definition of survivin overexpression also varied among studies. The cutoff value used to define survivin overexpression was 10% in most studies, whereas in the remaining two studies, the cut-off value was 8% and 20%, respectively [54,58]. Immunopositive cells were defined according to the percentage of nuclear [54,57,60], cytoplasmic [52] or both [55,58,62,63] staining. Four studies documented whether staining assessment was blinded to outcome status [52,57,60, 61]. The median quality score was recorded as 5 (range: 3-6). There was no significant correlation between study size and quality scores (Spearman's r = 0.472, p = 0.210).

The 14 eligible studies included a total of 2,165 patients, with a median number of 155 patients per study (range: 17-726). Basic sociodemographic information, such as sex and age, was missing from 28.6% and 28.6% of studies, respectively. Other characteristics such as the patient and tumor characteristics are summarized in the Appendices 1 and 2. Of the 1,755 patients available in the present study, survivin overexpression was detected in 846 (48.2%). There were higher frequencies of survivin overexpression with T stage and tumor grade were higher (Appendix 3).

Table 2 summarizes the methods for estimation of HR. nine (64.3%)
Forrest plots of the primary meta-analyses can be seen in Fig. 2. Fig. 2 reports the average (pooled) HR and its 95% CI for each of the meta-analysis in non-muscle invasive bladder tumor. There was some evidence from the meta-analyses that survivin status may provide prognostic information. The pooled HRs were statistically significant for recurrence-free survival (pooled HR, 1.81; 95% CI, 1.30-2.52), progression-free survival (pooled HR, 2.12; 95% CI, 1.60-2.82), cancer-specific survival (pooled HR, 2.01; 95% CI, 1.32-3.06), and overall survival (pooled HR, 1.53; 95% CI, 1.02-2.29).

In muscle invasive and advanced bladder tumors, the HRs were also statistically significant for recurrence-free survival (HR, 1.46; 95% CI, 1.18-1.82), cancer-specific survival (HR, 1.54; 95% CI, 1.21-1.96), and overall survival (HR, 2.46; 95% CI, 1.63-3.71). The results are shown in Fig. 4 and 5.

Only adjusted survival data were sufficient articles available to compare survival analyses according to survivin expression (Table 3), although this subgroup analysis only includes 2 studies with overall survival data available. Statistically significant differences were identified for all survival
subgroup analyses. Survivin overexpression was significantly associated with adverse survival in the pooled patient group. In addition, sensitivity analyses confirm that our estimate of the overall HR of recurrence-free survival, progression-free survival, cancer-specific survival and overall survival by survivin status is robust when IHC was chosen for the method for determination of survivin expression (Table 4).

Due to our attempts to limit between-study heterogeneity through our strict inclusion criteria, there was no between-study heterogeneity in the effect of survivin status on the majority of meta-analyses, with $I^2$ generally toward less than 50%. However, heterogeneity between overall survival results still remains within each subgroup and results should be interpreted cautiously.

Due to the small number of studies in most meta-analyses, it was not sensible to examine the potential for publication bias in meta-analysis, which did not contain 10 studies. However, there was no clear evidence of funnel plot asymmetry for outcomes, and thus, there was no clear evidence of publication bias (Fig. 3).
Currently, expression of survivin is being used as a novel prognostic factor in several human neoplasms. The rationale for investigating survivin as a prognostic marker in bladder cancer is based on its ability to inhibit apoptosis, promote proliferation and enhance angiogenesis, as well as its predominantly tumor-specific expression in adult tissues. In spite of suggested pivotal role of survivin as a prognostic marker, there are relatively few studies available exploring the role of survivin in bladder cancer, and some of them are controversial. In addition, the power of most individual studies was limited, due to low sample size. To date, no meta-analysis had been undertaken for any studies evaluating survivin as a prognostic marker in bladder cancer.

In this meta-analysis, which enrolled all the eligible studies comparing the survival of bladder cancer patients according to the tumor expression of survivin, survivin is a prognostic factor in bladder cancer. Statistical significance was reached when patients who received each treatment were enrolled into this analysis. Our results showed that survivin overexpression is strongly predictive of recurrence, progression and mortality in bladder cancer.

Generally, meta-analysis based on individual data is considered as a gold standard [64]. However, meta-analysis of prognostic literature is associated with a number of inherent limitations. One of these key
limitations is the general prevalence of retrospective study design in this setting. None of the studies included in the current meta-analysis specified a prospective design. It is difficult to draw any precise conclusions when studies are not conducted prospectively and when not all relevant data are available. Alongside this, an additional hindrance to meta-analysis of prognostic literature is the general lack of multivariable survival data in many of studies, although the REMARK guidelines state the investigation must include established clinicopathologic prognostic factors as part of a multivariate model, and report the resulting HRs regardless of statistical significance [11]. If the authors did not report the individual HR together with its variance, we calculated it from the survival comparison statistics and its variance, whenever possible. The estimated HR might be less reliable than the one obtained directly from published statistics. This is also attributable to the fact that the number of patients included in each study is typically small. However, when analyzing the overall relationship between individual study size and methodological quality scores in the present study, there was no significant trend towards superior methodological quality in larger studies.

Although the specimens and methods used for the assessment of survivin expression in patients with bladder cancer differed among these studies, many of the eligible studies used IHC to detect survivin expression. IHC results should be interpreted with caution, because of varying specificity of the antibodies used, different concentration of the antibody used, lack of standardized technology, different approaches for storing and
processing tissue, and the absence of a uniform definition of positive staining, leading to different results when using different cutoff points [65]. When defining survivin overexpression, the threshold in IHC varied from 8% to 20% among these studies. In patients with bladder cancer, there is no common threshold value in defining positive expression of survivin, but it is important that a common or standard threshold in the assessment of some biomarker should be set to make a comparatively accurate evaluation of its real function in clinical practice.

Survivin exists in two subcellular pools and this is consistent with its function in the regulation of both cell viability and cell division [66, 67]. Therefore, another problem with IHC is the determination of nuclear or cytoplasmic expression of survivin. Some studies pointed out the fact that survivin could be expressed in either cytoplasm or nuclei. For example, one study showed that survivin nuclear, but not cytoplasmic staining, correlated with tumor grade, stage, and patient outcome in patients with bladder cancer [54]. However, IHC results may sometimes lead to misjudgment or misinterpretation of the expression pattern of survivin in normal or cancerous tissues, due to inappropriate processing of either tissues or images [68]. In a review of the literature, Li et al [68] identified 19 publications that measured nuclear survivin in human tumors, and reported that conflicting findings existed on the relationship between nuclear survivin and prognosis. Among 19 publications, 9 showed that nuclear survivin expression is an unfavorable prognostic marker, whereas 5 proposed an opposing notion, i.e. that the nuclear survivin expression represented a
favorable prognostic marker. The remaining 5 publications did not focus on studying the significance of survivin nuclear expression in disease outcome. Most eligible studies did not investigate the differential predictive value of nuclear versus cytoplasmic staining of survivin. At present, it remains uncertain as to whether there is a difference when distinguishing between cytoplasmic or nuclear staining for survivin.

Although there was no heterogeneity for survival analysis, caution is perhaps advised, as there were only 14 studies with a relatively small sample size of patients in the analysis. Heterogeneity may be caused by other factors, such as inclusion criteria, different tumor stage, type of treatment, sample storage, primary antibody and dilution, method of measuring survivin, survivin cutoff levels, and adjustment for cofactors. It is also very difficult to examine or explain heterogeneity, due to the variability in clinical characteristics across patients within studies. In addition, there are few reports in the literature with respect to the prognostic impact of survivin in more advanced bladder cancer patients. Especially, only one study examined whether survivin overexpression might be a predictive marker for overall survival to cisplatin-based chemotherapy in patients with advanced (T4b and N2-N3) or metastatic (M1) bladder cancer [55].

Another potential source of bias is related to Language. This review was totally limited to literatures published in English because other languages were not accessible for the investigators. The restriction to English language articles possibly favors the positive results [69]. In addition, we did not extend the search to unpublished data that would likely
include increased proportions of null results. Furthermore, the pooled risks of survivin for recurrence-free survival or overall survival in non-muscle invasive bladder tumor, although statistically significant, were not strong, with pooled HRs of 1.81 and 1.53, respectively. Empirically, HR >2 is considered strongly predictive [70]. Finally, given the complexity of the molecular abnormalities associated with bladder cancer, combinations of independent, complementary markers might provide a more accurate prediction of outcome than a single marker [25,47,63].

Despite the inherent limitations of meta-analyzing prognostic literature, the findings from the present study suggest that survivin represents the consistently reproducible molecular marker with prognostic value in bladder cancer. Our strengths lie within the broad, unbiased search of the literature and the application of standardized systematic review and meta-analysis techniques to objectively identify manuscripts containing data sufficiently robust to be summarized. Strict inclusion/exclusion criteria were used to select the studies included in the present meta-analysis, thus limiting the potential bias. In cases where part or all of the same patients series was included in more than one publication, only the more recent or more complete study was included in the analysis, in order to avoid duplicating the same patient data. When considering the overall effects of potential publication bias in this analysis, the funnel plots for survival analysis were not indicative of any strong publication bias.
In conclusion, our meta-analysis has yielded significant association between survivin expression and bladder cancer recurrence, progression, and mortality, although these findings need to be interpreted with caution. It is difficult to draw any reliable conclusion for the current meta-analysis of survivin for overall survival in bladder cancer, due to the limited number of evaluable studies. Survivin determination might help identify patients with bladder cancer at high risk of disease recurrence, progression and poor prognosis, who might benefit from closer follow-up or more aggressive therapy. However, simplified, quantitative and reproducible assays need to be developed and validated for the detection of survivin. In addition, it is rather necessary that better designed studies need to be enrolled into such kind of analysis in the future, to provide a better conclusion about the relationship between survivin expression and the outcome of patients with bladder cancer. The value of survivin for molecular staging of bladder cancer also needs to be confirmed in controlled trials involving larger number of patients with longer follow-up, before any definitive conclusions can be made.
References

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.

2. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.

3. Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 2008;26:59-65.

4. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin Ther Targets 2008;12:463-76.

5. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: a promising tumor biomarker. Cancer Lett 2007;249:49-60.

6. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-34.

7. Kappler M, Kotzsch M, Bartel F, Füssel S, Lautenschläger C, Schmidt U, Würl P, Bache M, Schmidt H, Taubert H, Meye A. Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res 2003;9:1098-104.

8. Rödel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rödel C. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005;65:4881-7.

9. de Graeff P, Crijns AP, de Jong S, Boezen M, Post WJ, de Vries EG, van der Zee AG, de Bock GH. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer 2009;101:149-59.

10. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
11. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005;93:387-91.

12. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34.

13. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002;21:3337-51; Tierney JF, Stewart LA, Gherzi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.

14. Tierney JF, Stewart LA, Gherzi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.

15. Duchateau L, Collette L, Sylvester R, Pignon JP. Estimating number of events from the Kaplan-Meier curve for incorporation in a literature-based meta-analysis: what you don't see you can't get! Biometrics 2000;56:886-92.

16. Michiels S, Piedbois P, Burdett S, Syz N, Stewart L, Pignon JP. Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care 2005;21:119-25.

17. Hirooka T, Hamada C, Yoshimura I. A note on estimating treatment effect for time-to-event data in a literature-based meta-analysis. Methods Inf Med 2009;48:104-12.

18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.

19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.

20. Hausladen DA, Wheeler MA, Altieri DC, Colberg JW, Weiss RM. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome. J Urol 2003;170:230-4.
21. Wang H, Xi X, Kong X, Huang G, Ge G. The expression and significance of survivin mRNA in urinary bladder carcinomas. J Cancer Res Clin Oncol 2004;130:487-90.

22. Wu Y, Wang G, Wei J, Wen X. Survivin protein expression positively correlated with proliferative activity of cancer cells in bladder cancer. Indian J Med Sci 2005;59:235-42.

23. Mowla SJ, Emadi Bayegi M, Ziaee SA, Nikpoor P. Evaluating expression and potential diagnostic and prognostic values of survivin in bladder tumors: a preliminary report. Urol J 2005;2:141-7.

24. López-Knowles E, Hernández S, Kogevinas M, Lloreta J, Amorós A, Tardón A, Carrato A, Kishore S, Serra C, Malats N, Real FX; EPICURO Study Investigators. The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res 2006;12:6029-36.

25. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol 2007;25:468-75.

26. Margulis V, Shariat SF, Ashfaq R, Thompson M, Sagalowsky AI, Hsieh JT, Lotan Y. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol 2007;177:1163-8.

27. Schultz IJ, De Kok JB, Witjes JA, Babjuk M, Willems JL, Wester K, Swinkels DW, Tjalsma H. Simultaneous proteomic and genomic analysis of primary Ta urothelial cell carcinomas for the prediction of tumor recurrence. Anticancer Res 2007;27:1051-8.

28. Schultz IJ, Wester K, Straatman H, Kiemeney LA, Babjuk M, Mares J, Willems JL, Swinkels DW, Witjes JA, Malmström PU, de Kok JB. Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. Eur Urol 2007;51:416-22.

29. Nouraei N, Mowla SJ, Ozhand A, Parvin M, Ziaee SA, Hatefi N. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker. Urol J 2009;6:101-8.

30. Atlasi Y, Mowla SJ, Ziaee SA. Differential expression of survivin and its splice variants, survivin-DeltaEx3 and survivin-2B, in bladder cancer. Cancer Detect Prev 2009;32:308-13.
31. Pollard C, Nitz M, Baras A, Williams P, Moskaluk C, Theodorescu D. Genoproteomic mining of urothelial cancer suggests γ-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy. Am J Pathol 2009;175:1824-30.

32. Yildirim U, Erdem H, Kayikci A, Sahin AF, Uzunlar AK, Albayrak A. Cyclooxygenase-2 and survivin in superficial urothelial carcinoma of the bladder and correlation with intratumoural microvessel density. J Int Med Res 2010;38:1689-99.

33. Birkhahn M, Mitra AP, Williams AJ, Lam G, Ye W, Datar RH, Balic M, Groshen S, Steven KE, Cote RJ. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol 2010;57:12-20.

34. Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R, Lotan Y. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol 2010;183:1744-50.

35. Dong ZL, Lu ZP, Wang HZ, Zhang LY, Wang ZP, Zhang YF, Ma BL. Detection of nuclear matrix protein 22 and survivin baseline level in patients after radical cystectomy. Urol Int 2011;87:445-9.

36. Patschan O, Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Lotan Y, Hotakainen K, Stenman UH, Bjartell A. Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder. World J Urol 2012;30:785-94.

37. Jaiswal PK, Goel A, Mandhani A, Mittal RD. Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort. Mol Biol Rep 2012;39:5615-21.

38. Xi RC, Sheng YR, Chen WH, Sheng L, Gang JJ, Tong Z, Shan Z, Ying GH, Dong LC. Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer. J Surg Oncol 2013;107:550-4.

39. Sun YW, Xuan Q, Shu QA, Wu SS, Chen H, Xiao J, Xiang P, Zhu YP, Wang FL, Zhao ST. Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma. Genet Mol Res 2013;12:1045-53.
40. Lehner R, Lucia MS, Jarboe EA, Orlicky D, Shroyer AL, McGregor JA, Shroyer KR. Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol 2002;10:134-8.

41. Weikert S, Christoph F, Schrader M, Krause H, Miller K, Müller M. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 2005;116:100-4.

42. Wang Y, Zhu Z, Zeng F, Wang L, Wu Y, Xia W, Xing S. Expression and prognostic significance of survivin in the progression of bladder transitional cell cancer. J Huazhong Univ Sci Technolog Med Sci 2007;27:444-7.

43. Kitsukawa S, Aoyagi T, Noda K, Ito T, Yamamoto Y, Hosoda S, Otsuru N, Matsumoto T. Quantitative analysis of survivin mRNA expression in bladder transitional cell carcinomas. Hinyokika Kiyo 2008;54:101-6.

44. Gonzalez S, Aubert S, Kerdraon O, Haddad O, Fantoni JC, Biserte J, Leroy X. Prognostic value of combined p53 and survivin in pT1G3 urothelial carcinoma of the bladder. Am J Clin Pathol 2008;129:232-7.

45. Jang TJ, Lee KS. The expression of cyclooxygenase-2 and survivin in urinary bladder transitional cell carcinoma Korean J Pathol 2009;43:206-11.

46. Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, Neckers L, Kihara K. ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer. PLoS One 2011;6:e27616.

47. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007;8:128-36.

48. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007;109:1106-13.

49. Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, Isbarn H, Jeldres C, Rigaud J, Sagalowsky AI, Lotan Y. Predictive value
of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 2009;182:78-84.

50. Gazzaniga P, Gradilone A, Giuliani L, Gandini O, Silvestri I, Nofroni I, Saccani G, Frati L, Agliano AM. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 2003;14:85-90.

51. Schultz IJ, Kiemenej LA, Witjes JA, Schalken JA, Willems J, Swinkels DW, de Kok JB. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 2003;23:3327-31.

52. Ku JH, Kwak C, Lee HS, Park HK, Lee E, Lee SE. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 2004;171:631-5.

53. Schultz IJ, Kiemenej LA, Karthaus HF, Witjes JA, Willems J, Swinkels DW, Gunnewiek JM, de Kok JB. Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin Chem 2004;50:1425-8.

54. Yin W, Chen N, Zhang Y, Zeng H, Chen X, He Y, Wang X, Zhou Q. Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder. Mod Pathol 2006;19:1487-97.

55. Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology 2007;70:482-6.

56. Pina-Cabral L, Santos L, Mesquita B, Amaro T, Magalhães S, Criado B. Detection of survivin mRNA in urine of patients with superficial urothelial cell carcinomas. Clin Transl Oncol 2007;9:731-6.

57. Skagias L, Politi E, Karameris A, Sambaziotos D, Archondakis A, Ntinas A, Moreas I, Vasou O, Koutselini H, Patsouris E. Survivin expression as a strong indicator of recurrence in urothelial bladder cancer. Predictive value of nuclear versus cytoplasmic staining. Anticancer Res 2009;29:4163-7.

58. Weiss C, von Römer F, Capalbo G, Ott OJ, Wittlinger M, Krause SF, Sauer R, Rödel C, Rödel F. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with
transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys 2009;74:1455-60.

59. Gradilone A, Petracca A, Nicolazzo C, Gianni W, Cortesi E, Naso G, Vincenzi B, Cristini C, De Berardinis E, Di Silverio F, Agliano AM, Gazzaniga P. Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int 2010;106:710-5.

60. Fristrup N, Ulhøi BP, Birkenkamp-Demtröder K, Mansilla F, Sanchez-Carbaya M, Segersten U, Malmström PU, Hartmann A, Palou J, Alvarez-Múgica M, Zieger K, Borre M, Ørntoft TF, Dyrskjøt L.. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol 2012;180:1824-34.

61. Xi RC, Sheng YR, Chen WH, Sheng L, Gang JJ, Tong Z, Shan Z, Ying GH, Dong LC. Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer. J Surg Oncol 2013;107:550-4.

62. Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Müller SC, Sagalowsky AI, Lotan Y. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res 2009;15:7012-9.

63. Als AB, Dyrskjøt L, von der Maase H, Koed K, Mansilla F, Toldbod HE, Jensen JL, Ulhøi BP, Sengeløv L, Jensen KM, Orntoft TF. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007;13:4407-14.

64. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993;341:418-22.

65. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-35.

66. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM, Tognin S, Marchisio PC, Altieri DC. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002;115:575-85.
67. Li F, Ling X. Survivin study: an update of "what is the next wave"? J Cell Physiol 2006;208:476-86.

68. Li F, Yang J, Ramnath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 2005;114:509-12.

69. Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997;350:326-9.

70. Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 2001;6:375-92.
| Study     | Year | Country | Recruitment period | Study design | Inclusion and exclusion criteria | Consecutive Patients | Specimen | Method | Compartmen t | Cut-off | Definition of survival | Blind assessment | Quality Assessment (0-8) |
|-----------|------|---------|--------------------|--------------|----------------------------------|----------------------|----------|--------|---------------|---------|------------------------|------------------|--------------------------|
| Gazzaniga  | 2003 | Italy   | 1996-1998          | Retrospective | No                               | NA                   | Tissue   | RT-PCR |              | -       | yes                    | NA               | 5                        |
| Schultz   | 2003 | Netherlands | NA           | Retrospective | No                               | NA                   | Tissue   | Real-time RT-PCR | -       | 0.2 6*                  | yes              | NA                       | 5                        |
| Ku        | 2004 | Korea   | 1993-1997          | Retrospective | No                               | No                   | Tissue   | IHC     | Cytoplasm     | 20%     | yes                    | blind            | 5                        |
| Schultz   | 2004 | Netherlands | NA           | Retrospective | No                               | NA                   | Urine    | Real-time RT-PCR | -       | 0.1 3*                  | yes              | NA                       | 3                        |
| Yin       | 2006 | China   | NA                 | Retrospective | No                               | Yes                  | Tissue   | IHC     | Nuclear       | 8%      | no                     | NA               | 4                        |
| Karam     | 2007 | USA     | 1995-2003          | Retrospective | No                               | NA                   | Tissue   | IHC     | Nuclear or cytoplasm | 10%     | yes                    | NA               | 3                        |
| Pina-Cabral| 2007| Portugal | NA                | Retrospective | No                               | NA                   | Urine    | RT-PCR |              | -       | yes                    | NA               | 3                        |
| Skagias   | 2009 | Greece  | 1998-2005          | Retrospective | No                               | NA                   | Tissue   | IHC     | Nuclear       | 10%     | yes                    | blind            | 5                        |
| Weiss     | 2009 | Germany | 1982-2004          | Retrospective | No                               | No                   | Tissue   | IHC     | Nuclear or cytoplasm | 20%     | yes                    | NA               | 5                        |
| Gradilone | 2010 | Italy   | NA                 | Retrospective | Yes                              | NA                   | Tissue   | RT-PCR |              | -       | no                     | NA               | 4                        |
| Fristrup (Denmark) | 2012 | Denmark | 1979-2007          | Retrospective | No                               | NA                   | Tissue   | IHC     | Nuclear       | 10%     | yes                    | blind            | 5                        |
| Fristrup (validation 1) | 2012 | Sweden  | 1984-2005          | Retrospective | No                               | NA                   | Tissue   | IHC     | Nuclear       | 10%     | yes                    | blind            | 5                        |
| Fristrup (validation 2) | 2012 | Spain   | 1984-2008          | Retrospective | No                               | NA                   | Tissue   | IHC     | Nuclear       | 10%     | yes                    | blind            | 5                        |
| Xia       | 2013 | China   | 2000-2006          | Retrospective | Yes                              | No                   | Tissue   | IHC     | NA            | 10%     | yes                    | blind            | 6                        |
| Sharia    | 2009 | Multinational | 1983-2005 | Retrospective | Yes                              | No                   | Tissue   | IHC     | Nuclear or cytoplasm | 10%     | yes                    | NA               | 4                        |
| Als       | 2007 | Denmark | 1995-2004          | Retrospective | Yes                              | NA                   | Tissue   | IHC, microarray | with an intensity of 2 or 3 | 10%     | no                     | NA               | 6                        |

*survivin mRNA copy number/cyclophilin mRNA copy number
NA: not available, RT-PCR: reverse transcriptase-polymerase chain reaction, IHC: immunohistochemistry.
| Study          | Survival analysis   | HR estimation                                                                 | Co-factors                                                                 | Analysis results |
|---------------|---------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------|------------------|
| Gazzaniga     | recurrence-free     | p value, event number (univariate)                                          | -                                                                          | not significant  |
| Schultz       | recurrence-free     | absence of eligible data                                                     | -                                                                          | significant      |
|                | progression-free    | p value, event number (univariate)                                          | -                                                                          | not significant  |
|                | cancer-specific     | absence of eligible data                                                     | -                                                                          | not significant  |
| Ku            | recurrence-free     | HR, 95% CI (multivariate)                                                    | age, sex, size, number, architecture, grade, T stage                      | significant      |
| Schultz       | recurrence-free     | p value, event number (univariate)                                          | age, grade, T stage, grade and stage, ki67, BIRC5-C                       | significant      |
| Yin           | progression-free    | HR, 95% CI (multivariate)                                                    | age, grade, T stage, grade and stage, ki67, BIRC5-C                       | significant      |
| Karam         | recurrence-free     | HR, 95% CI (multivariate)                                                    | grade, T stage, intravesical therapy                                     | significant      |
| Skagias       | progression-free    | HR, 95% CI (multivariate)                                                    | grade, T stage, intravesical therapy                                     | significant      |
| Weiss         | recurrence-free     | HR, 95% CI (multivariate)                                                    | grade, T stage                                                           | not significant  |
|                | progression-free    | HR, 95% CI (multivariate)                                                    | grade, T stage                                                           | not significant  |
|                | cancer-specific     | HR, 95% CI (multivariate)                                                    | circulating tumor cell                                                   | not significant  |
| Gradilone     | recurrence-free     | HR, 95% CI (multivariate)                                                    | cathepsin E, maspin, PIK1                                                | significant      |
| Fristrup (Denmark) | progression-free | HR, 95% CI (multivariate)                                                    | cathepsin E, maspin, PIK1                                                | significant      |
| Fristrup (validation) | overall        | HR, 95% CI (multivariate)                                                    | cathepsin E, maspin, PIK1                                                | significant      |
| Xi            | progression-free    | HR, 95% CI (multivariate)                                                    | grade, T stage, livin                                                     | significant      |
| Shariat       | recurrence-free     | HR, 95% CI (multivariate)                                                    | Age, sex, grade, pT stage, N stage, surgical margin, LVI, concomitant CIC, ACH | significant      |
| Als           | cancer-specific     | HR, 95% CI (multivariate)                                                    | Age, sex, grade, pT stage, N stage, surgical margin, LVI, concomitant CIC, ACH | significant      |
|               | overall             | HR, 95% CI (multivariate)                                                    | visceral metastasis, emmprin                                              | significant      |

HR: hazard ratio, CI: confidence interval, BIRC5-C: cytoplasmatic staining of survivin, LVI: lymphoascular invasion, CIS: carcinoma in situ, ACH: adjuvant chemotherapy.
Table 3. Summary of subgroup survival analysis in non-muscle invasive bladder tumor

|                                | No. of included articles | No. of cases | Pooled HR (95% CI) | I²  | Chi² (p value) |
|--------------------------------|--------------------------|-------------|--------------------|-----|----------------|
| Recurrence-free survival       | 5*                       | 368         | 2.09 (1.27-3.45)   | 27% | 5.45 (0.24)    |
| Progression-free survival      | 4”                       | 868         | 2.17 (1.59-2.97)   | 8%  | 3.27 (0.35)    |
| Cancer-specific survival       | 3’                       | 458         | 2.17 (1.26-3.73)   | 33% | 2.99 (0.22)    |
| Overall survival               | 2’                       | 363         | 1.53 (1.02-2.29)   | 0%  | 0.13 (0.72)    |

HR: hazard ratio, CI: confidence interval.
References: [52,55,57,59,61].
References: [54,55,60 (Denmark cohort), 60 (validation cohort)].
References: [54,55,60 (Denmark cohort)].
References: [57,60 (Denmark cohort)].
### Table 4. Summary of sensitivity analysis in non-muscle invasive bladder tumor

|                      | No. of included articles | No. of cases | Pooled HR (95% CI)       | I²  | Chi² (p value) |
|----------------------|--------------------------|--------------|--------------------------|-----|----------------|
| Recurrence-free survival | 5<sup>*</sup>          | 362          | 2.32 (1.53-3.52)         | 0%  | 3.52 (0.48)    |
| Progression-free survival | 5<sup>**</sup>         | 916          | 2.15 (1.62-2.86)         | 0%  | 3.27 (0.51)    |
| Cancer-specific survival    | 4<sup>†</sup>         | 506          | 2.01 (1.32-3.06)         | 7%  | 3.21 (0.36)    |
| Overall survival          | 2<sup>†</sup>          | 363          | 1.53 (1.02-2.29)         | 0%  | 0.13 (0.72)    |

HR: hazard ratio, CI: confidence interval.

<sup>*</sup>References: [52,55,57,58,61].

<sup>**</sup>References: [54,55,58,60 (Denmark cohort),60 (validation cohort)].

<sup>†</sup>References: [54,55,58,60 (Denmark cohort)].

References: [57,60 (Denmark cohort)].
Table S1. Patient characteristics of included studies

| Study            | No. Patients | Median age (yr) | Gender (m/f) | Treatment       | Adjuvant treatment                          | Median FU, range (mon) |
|------------------|--------------|-----------------|--------------|-----------------|---------------------------------------------|------------------------|
| Gazzaniga\textsuperscript{10} | 30           | 65.0, 27-85     | NA           | TURBT           | 11 (intravesical MMC) 7 (intravesical BCG) | 39.0 (mean), 27-51    |
| Schultz\textsuperscript{52}      | 17           | NA              | NA           | TURBT           | 17 (intravesical)                           | 70.8 (mean), 2-180    |
| Ku\textsuperscript{53}           | 88           | 60 (mean), 23-92| 80/8         | TURBT           | NA                                          | 63, 1-113              |
| Schultz\textsuperscript{54}      | 26           | NA              | NA           | TURBT           | 13 (intravesical)                           | 32.6 (mean), 1-45     |
| Yin\textsuperscript{55}          | 101          | NA              | 81/20        | TURBT           | 101 (intravesical BCG)                      | 54, 20-68.6 (10-90\% percentiles) |
| Karam\textsuperscript{56}        | 74           | 63.2, 41.1-89.3 | 60/14        | TURBT           | 54 (intravesical MMC or BCG)                | 42.3, 0.3-124.6       |
| Pina-Cabra\textsuperscript{57}   | 30           | 74.5, 39-86     | 23/7         | TURBT           | 17 (intravesical MMC or BCG)                | 22.3, 2.8-41.4        |
| Skagias\textsuperscript{58}      | 80           | 65 (mean), 26-85| 69/11        | TURBT or radical cystectomy                   | NA                      | 33.9 (mean), 12-96 |
| Weiss\textsuperscript{59}        | 48           | 71, NA          | 40/8         | TURBT           | 8 (RT), 40 (CRT)                            | 27.0, 3-140           |
| Gradlone\textsuperscript{11}     | 54           | 57.5, 51-64     | NA           | TURBT           | 54 (intravesical BCG)                       | 17.9 (mean), 3-24     |
| Fristrup (Denmark)\textsuperscript{60} | 283 | 68, 32-86       | 222/61       | TURBT           | 70 (intravesical MMC or BCG)                | 103, 2-263            |
| Fristrup (validation1)\textsuperscript{60} | 141 | 70, 31-96       | 112/29       | TURBT           | NA                                          | 72, 1-193             |
| Fristrup (validation2)\textsuperscript{60} | 269 | 68, 25-89       | 233/36       | TURBT           | 193 (intravesical MMC or BCG)               | 99, 3-205             |
| X\textsuperscript{61}            | 72           | NA              | 59/13        | TURBT           | 61 (intravesical or systemic chemotherapy)  | 51 (mean), 21-60      |
| Shariat\textsuperscript{62}      | 726          | 68, 34-94       | 600/126      | radical cystectomy                              | 187 (systemic chemotherapy) | 53.3, 0.1-235.6       |
| Als\textsuperscript{59}          | 25           | (microarray), 51.5, 49-74 | 24/6 (microarray), 62.6 (31-78 (IHC) | TURBT | 11 (RT or surgery) | 81.8, 56.7-98.0 (microarray), 56.5, 19.5-129.8 (IHC) |

FU: follow-up, NA: not available, TURBT: transurethral resection of bladder tumor, MMC: mitomycin C, BCG: bacillus Calmette-Guérin, RT: radiotherapy, CRT: chemoradiotherapy, IHC: immunohistochemistry.
| Study       | T stage (Ta/Tis/T1) | Concomitant CIS | Tumor grade (G1/G2/G3) | Multiplicity (single/multiple) | Tumor architecture (papillary/solid/mixed) | Tumor size (<3cm/≥3cm) | Positive survivin expression |
|------------|---------------------|----------------|------------------------|-------------------------------|------------------------------------------|------------------------|-----------------------------|
| Gazzaniga   | 9/0/21              | NA             | 21/9/0                 | 17/13/0                       | NA/NA/NA/NA                             | NA/NA/NA/NA            | 9                           |
| Schultz52   | NA/NA/NA            | NA             | NA/NA/NA/NA            | NA/NA/NA/NA                  | 79/9/0                                   | 75/13/0                | 8                           |
| Ku53        | 44/0/44             | NA             | 20/47/21               | 48/40/0                       | NA/NA/NA/NA                             | 51                     | 13                          |
| Schultz54   | NA/NA/NA            | NA             | NA/NA/NA/NA            | NA/NA/NA/NA                  | 52/28/28 (LG)/28 (HG)                    | 52                     | 28                          |
| Yin55       | 54/0/47             | 0              | 59 (LG)/42 (HG)        | NA/NA/NA/NA                  | NA/NA/NA/NA                             | 39                     | 20                          |
| Karam56     | 26/13/35            | NA             | 7/32/35                | NA/NA/NA/NA                  | NA/NA/NA/NA                             | 32                     | 20                          |
| Pina-Cabral57| 15/2/13            | NA             | 16/10/4                | 14/16/0                       | NA/NA/NA/NA                             | 49                     | 49                          |
| Skagias58   | 51/0/15/14 (≥T2)    | NA             | 52 (LG)/28 (HG)        | NA/NA/NA/NA                  | NA/NA/NA/NA                             | 27                     | 27                          |
| Weiss58     | 0/0/48              | 14             | 12 (G12)/36            | 24/24/0                       | NA/NA/NA/NA                             | 177/72/34              | 98                          |
| Gradilone   | 0/0/54              | 0              | 0/0/54                 | 54/0/0                       | NA/NA/NA/NA                             | 169/87/27              | 98                          |
| Fristrup (Denmark)50 | 182/0/101     | 95             | 183 (LG)/100 (HG)      | 248/20/14                     | 169/87/27                               | 177/72/34              | 98                          |
| Fristrup (validation1)60 | 67/0/74       | NA             | 47 (LG)/94 (HG)        | NA/NA/NA/NA                  | NA/NA/NA/NA                             | NA/NA/NA/NA            | NA                          |
| Fristrup (validation2)60 | 21/0/248     | 70             | 103 (LG)/166 (HG)      | 230/22/17                     | 169/87/27                               | 167/78/4               | NA                          |
| Xi51        | 25 (TaTis)/47       | NA             | 41 (G12)/31            | NA/NA/NA/NA                  | NA/NA/NA/NA                             | 61                     | 61                          |
| Shariat62   | 90 (T1)/208 (T2)/309| NA             | 108 (LG)/618 (HG)      | NA/NA/NA/NA                  | NA/NA/NA/NA                             | 359                    | 359                         |
| Als53       | 124 (≥T4b)          | NA             | NA/NA/NA/NA            | NA/NA/NA/NA                  | NA/NA/NA/NA                             | NA/NA/NA/NA            | NA/NA/NA/NA                 |

CIS: carcinoma in situ, NA: not available, LG: low grade, HG: high grade.
| T stage          | Concomitant CIS | Tumor grade | Multiplicity | Tumor architecture | Tumor size |
|------------------|-----------------|-------------|--------------|--------------------|------------|
|                  |                 | G1          | G2           | G3                 | NA         | NA         | 3cm         | ≥3cm      | NA        |
|      Ta          | 1/9             | 8/21        | NA           | 1/2                | 6/17       | NA         | NA          | NA        | NA        |
|      Tis         | 0/0             | 1           | 8/9          | 0/0                | 3/13       | NA         | NA          | NA        | NA        |
|      T1          | 22/4            | 29/44       | NA           | 35/67 (G12)        | 16/21      | NA         | NA          | NA        | NA        |
| Schultz a 10     | NA              | NA          | NA           | 27/48              | 4/9        | 0/0        | 1            | 43/75     | 8/13      | 0/0       |
|      Ku 53       | NA              | NA          | NA           | 22/4               | 37/62      | NA         | NA          | NA        | NA        |
|      Karam 56    | NA              | NA          | NA           | 11/2               | 13/38      | NA         | NA          | NA        | NA        |
|      Pinacabras 57 | 37/66           | 12/14       | NA           | 8/1                | 4/4        | 0/0        | 1            | 62/75     | 28/72     | 9/34      |
| Skagias 58       | (≤T1)           | (≥T2)       | NA           | 25/52 (LG),24/28 (HG) | NA         | NA         | NA          | NA        | NA        |
| Weiss 59         | 0/0             | 32/48       | 8/14         | 4/12 (G12)         | 33/36      | NA         | NA          | NA        | NA        |
| Gradilone 61     | 11/1            | 18/2        | 40/95        | 49/183 (LG),49/100 (HG) | 55/169      | 36/87      | 7/27        | 8/14      | 61/177    | 28/72     | 9/34      |
| Fristrup (Denmark) 68 | 19/25           | 42/47       | NA           | 31/41 (G12)        | 30/31      | NA         | NA          | NA        | NA        |
| Fristrup (validatiation 1) 69 | 44/90 (T1), 81/208 (T2), 162/309 (T3), 72/119 (T4) | NA | 59/108(LG),300/618 (HG) | NA         | NA         | NA          | NA        | NA        |
| Fristrup (validatiation 2) 70 | 44/90 (T1), 81/208 (T2), 162/309 (T3), 72/119 (T4) | NA | 59/108(LG),300/618 (HG) | NA         | NA         | NA          | NA        | NA        |
| Shafie 62        | NA              | NA          | NA           | NA                 | NA         | NA         | NA          | NA        | NA        |
| Ali 53          | NA              | NA          | NA           | NA                 | NA         | NA         | NA          | NA        | NA        |

CIS: carcinoma in situ, NA: not available, LG: low grade, HG: high grade
Fig 1. Methodological flow chart of the systematic review
**Fig. 2.** Forest plots of hazard ratios with random effects model for survivin in patients with non-muscle invasive bladder tumor. (A) Recurrence-free survival. (B) Progression-free survival. (C) Cancer-specific survival. (D) Overall survival.
Fig. 3. Funnel graphs of the assessment of potential publication bias in studies of survivin expression in patients with non-muscle invasive bladder tumor. (A) Recurrence-free survival. (B) Progression-free survival. (C) Cancer-specific survival. (D) Overall survival.
**Fig. 4.** Forest plots of hazard ratios with random effects model for survivin in patients with muscle invasive bladder tumor. (A) Recurrence-free survival. (B) Cancer-specific survival.

**Fig. 5.** Forest plots of hazard ratios with random effects model for surviving in patients with advanced or metastatic bladder tumor (overall survival).
### Appendix 1. Patient characteristics of included studies

| Study                  | No. Patients of | Median age, range (yr) | Gender (m/f) | Treatment | Adjuvant treatment                      | Median FU, range (mon) |
|------------------------|-----------------|------------------------|--------------|-----------|----------------------------------------|------------------------|
| Gazzaniga              | 30              | 65.0, 27-85            | NA           | TURBT     | 11 (intravesical MMC)                  | 39.0 (mean), 27-51    |
| Schultz Ku             | 17, 88          | NA                     | NA           | TURBT     | 7 (intravesical BCG)                   | 70.8 (mean), 2-180    |
|                       |                 | 60 (mean), 23-92       | 80/8         | TURBT     | 17 (intravesical)                      | 63, 1-113             |
| Schultz Yin            | 26, 101         | NA                     | NA           | TURBT     | 13 (intravesical)                      | 32.6 (mean), 1-45     |
| Karam                  | 74              | 63.2, 41.1-89.3        | 60/14        | TURBT     | 101 (intravesical BCG)                 | 54, 20-68.6 (10-90% percentiles) |
| Pina-Cabral            | 30              | 74.5, 39-86            | 23/7         | TURBT     | 54 (intravesical MMC or BCG)          | 42.3, 0.3-124.6       |
| Skagias                | 80              | 65 (mean), 26-85       | 69/11        | TURBT or  | NA                                     | 33.9 (mean), 12-96    |
|                       |                 |                        | radical      | cystectomy |                                       |                        |
| Weiss                  | 48              | 71, NA                 | 40/8         | TURBT     | 8 (RT), 40 (CRT)                       | 27.0, 3-140           |
| Gradilone              | 54              | 57.5, 51-64            | NA           | TURBT     | 54 (intravesical BCG)                  | 17.9 (mean), 3-24     |
| Fristrup (Denmark)     | 283             | 68, 32-86              | 222/61       | TURBT     | 70 (intravesical MMC or BCG)          | 103, 2-263            |
| Fristrup (validation1) | 141             | 70, 31-96              | 112/29       | TURBT     | NA                                     | 72, 1-193             |
| Fristrup (validation2) | 269             | 68, 25-89              | 233/36       | TURBT     | 193 (intravesical MMC or BCG)         | 99, 3-205             |
| X                      | 72              | NA                     | 59/13        | TURBT     | 61 (intravesical or systemic chemotherapy) | 51 (mean), 21-60      |
| Shariat                | 726             | 68, 34-94              | 600/126      | radical   | 187 (systemic chemotherapy)           | 53.3, 0.1-235.6       |
|                       |                 |                        | cystectomy   | systemic chemotherapy | | |
| Als                    | 25, 101 (IHC)   | 51.5, 49-74            | 24/6         | TURBT     | 11 (RT or surgery)                     | 81.8, 56.7-98.0 (microarray), 56.5, 19.5-129.8 (IHC) |
|                       |                 | 62.6, 31-78 (IHC)      |              |           |                                        |                        |

FU: follow-up, NA: not available, TURBT: transurethral resection of bladder tumor, MMC: mitomycin C, BCG: bacillus Calmette-Guérin, RT: radiotherapy, CRT: chemoradiotherapy, IHC: immunohistochemistry.
## Appendix 2. Tumor characteristics of included studies

| Study                  | T stage (Ta/Tis/T1) | Concomitant CIS | Tumor grade (G1/G2/G3) | Multiplicity (single/multiple/NA) | Tumor architecture (papillary/solid/mixed) | Tumor size (<3cm/≥3cm/NA) | Positive survivin expression |
|------------------------|---------------------|-----------------|------------------------|-----------------------------------|-------------------------------------------|--------------------------|-----------------------------|
| Gazzaniga             | 9/0/21              | NA              | 21/9/0                 | 17/13/0                           | NA/NA/NA                                 | NA/NA/NA                 | 9                           |
| Schultz                | NA/NA/NA            | NA              | NA/NA/NA               | NA/NA/NA                          | NA/NA/NA                                 | NA/NA/NA                 | 8                           |
| Ku                     | 44/0/44             | NA              | 20/47/21               | 48/40/0                           | 79/9/0                                    | 75/13/0                  | 51                          |
| Schultz                | NA/NA/NA            | NA              | NA/NA/NA               | NA/NA/NA                          | NA/NA/NA                                 | NA/NA/NA                 | 13                          |
| Yin                    | 54/0/47             | 0               | 59 (LG)/42 (HG)        | NA/NA/NA                          | NA/NA/NA                                 | NA/NA/NA                 | 28                          |
| Karam                  | 26/13/35            | NA              | 7/32/35                | NA/NA/NA                          | NA/NA/NA                                 | NA/NA/NA                 | 39                          |
| Pina-Cabral            | 15/2/13             | NA              | 16/10/4                | 14/16/0                           | NA/NA/NA                                 | NA/NA/NA                 | 20                          |
| Skagias                | 51/0/15/14 (≥T2)    | NA              | 52 (LG)/28 (HG)        | NA/NA/NA                          | NA/NA/NA                                 | NA/NA/NA                 | 49                          |
| Weiss                  | 0/0/48              | 14              | 12 (G12)/36            | 24/24/0                           | NA/NA/NA                                 | NA/NA/NA                 | 32                          |
| Gradilone              | 0/0/54              | 0               | 0/0/54                 | 54/0/0                            | 54/0/0                                    | NA/NA/NA                 | 27                          |
| Fristrup (Denmark)     | 182/0/101           | 95              | 183 (LG)/100 (HG)      | 169/87/27                         | 248/20/14                                 | 177/72/34                | 98                          |
| Fristrup (validation 1)| 67/0/74             | NA              | 47 (LG)/94 (HG)        | NA/NA/NA                          | NA/NA/NA                                 | NA/NA/NA                 | NA                          |
| Fristrup (validation 2)| 21/0/248            | 70              | 103 (LG)/166 (HG)      | NA/NA/NA                          | 230/22/17                                 | 187/78/4                 | NA                          |
| Xi                     | 9 (Ta/Tis)/47        | NA              | 41 (G12)/31            | NA/NA/NA                          | NA/NA/NA                                 | NA/NA/NA                 | 61                          |
| Shariat                | 90 (T1)/208 (T2)/309 | NA              | 108 (LG)/618 (HG)      | NA/NA/NA                          | NA/NA/NA                                 | NA/NA/NA                 | 359                         |
| Als                    | 124 (≥T4b)          | NA              | NA/NA/NA               | NA/NA/NA                          | NA/NA/NA                                 | NA/NA/NA                 | 52                          |

CIS: carcinoma in situ, NA: not available, LG: low grade, HG: high grade.
| T stage | Concomitant CIS | Tumor grade | Multiplicity | Tumor architecture | Tumor size |
|---------|----------------|-------------|--------------|--------------------|------------|
| Ta      | 1/9            | G1          | single       | NA                 | 3c         |
| Tis     | 0/0            | G2          | multiple     | NA                 | ≥3cm       |
| T1      | 8/21           | G3          | 6/17         | NA                 | NA         |
| NA      | NA             | NA          | 0/0          | NA                 | NA         |
| NA      | NA             | NA          | 1/12         | NA                 | NA         |
| Schultz | NA             | NA          | NA           | NA                 | NA         |
| Ku      | 35/67 (G12)    | 16/2        | 27/48        | NA                 | 43/75      |
| Schultz | 27/48          | 27/40       | 27/40        | NA                 | 43/813     |
| Yin     | 47/79          | 4/9         | 0/0          | NA                 | 0/0        |
| Karam   | 11/14          | 11/14       | 11/14        | NA                 | NA         |
| Pina-Cabral | 9/16 | 9/16       | 0/0          | NA                 | NA         |
| Skagias | 8/16           | 8/16        | 15/24        | NA                 | NA         |
| Weiss   | 8/12 (G12)     | 8/12        | 17/24        | NA                 | NA         |
| Gradilone | 5/24        | 5/24        | 17/24        | NA                 | NA         |
| Fristrup | 5/24       | 5/24        | 17/24        | NA                 | NA         |
| Fristrup | 5/24       | 5/24        | 17/24        | NA                 | NA         |
| Fristrup | 5/24       | 5/24        | 17/24        | NA                 | NA         |
| Fristrup | 5/24       | 5/24        | 17/24        | NA                 | NA         |
| Fristrup | 5/24       | 5/24        | 17/24        | NA                 | NA         |
| Fristrup | 5/24       | 5/24        | 17/24        | NA                 | NA         |
| Fristrup | 5/24       | 5/24        | 17/24        | NA                 | NA         |
| Fristrup | 5/24       | 5/24        | 17/24        | NA                 | NA         |
| Fristrup | 5/24       | 5/24        | 17/24        | NA                 | NA         |
| Fristrup | 5/24       | 5/24        | 17/24        | NA                 | NA         |
| Shariat | 5/24          | 5/24        | 17/24        | NA                 | NA         |
| Als     | 5/24           | 5/24        | 17/24        | NA                 | NA         |

CIS: carcinoma in situ, NA: not available, LG: low grade, HG: high grade.
Appendix 4. Forest plots of hazard ratios with random effects model for survivin in patients with muscle invasive bladder tumor. (A) Recurrence-free survival. (B) Cancer-specific survival.

Appendix 5. Forest plots of hazard ratios with random effects model for survivin in patients with advanced or metastatic bladder tumor (overall survival).
국문초록

방광암에서 survivin의 예후적 가치

- 체계적 문헌고찰과 메타분석 -

전찬후
학번: 2013-21699
서울대학교 의학과 비뇨기과학 교실

서론: Survivin은 세포 사멸을 억제하고 세포 분열을 조절하는 단백물질로서, 태아조직과 암세포에서 주로 발현되어 신생 종양의 성장을 촉진하는 것으로 알려져 있다. 방광암의 예후와 관련이 있는 종양 표지자로서의 가능성이 제시된 바 있지만, 모든 선행연구에서 다 같은 의견을 나타내지는 않았다. 이에 본 저자는 지금까지 출판된 논문의 체계적 문헌고찰과 메타분석을 통해 survivin의 발현이 방광암 예후에 미치는 영향을 분석하였다.

방법: 1997년 8월-2013년 5월까지의 Pubmed, Cochrane Library, SCOPUS 데이터베이스를 통해 얻은 자료에 대하여 체계적 문헌고찰을 통한 메타분석을 시행하였다.

결과: 총 463개의 논문 중 본 연구에 적합한 14개의 논문을 선정하였고, 총 2,165명의 환자의 자료를 분석하였다. 14개의 논문 중 포르말린 고정을 이용한 조직 제작 후 면역염색을 한 논문은 9개였다. 표재성 방광암으로 진단된 환자의 통합 위험도비(Hazard Ratio)는 각각 무재발 생존률 (HR=1.81,
95% confidence interval (1.30-2.52), 무진행 생존율 (HR=2.12, (1.60-2.82)), 종양 특이 생존율 (HR=2.01, (1.32-3.06)), 전체 생존율 (HR=1.53, (1.02-2.29))로 survivin 의 발현은 표재생 방광암의 예후에 악영향을 미쳤다. 진행성 병기인 환자에서 통합 위험도비는 표재생 에서보다 더 높게 나타났다. 보정된 생존자료를 통한 하위 그룹 분석 시, 모든 생존율 지표에서 survivin 의 발현은 방광암 예후에 좋지 않은 영향을 미치는 것을 알 수 있었다. 본 연구의 메타분석에서 survivin 의 영향에 대한 연구간 이질성은 없었고, 출판 편향의 증거 또한 없었다.

결론: 위 결과는 survivin 발현과 방광암의 예후가 밀접한 관련이 있다는 것을 보여주고 있다. 그러나, survivin 발현과 방광암 환자의 예후와의 관계에 대한 더 확실한 결론을 얻기 위해서는 표준화된 분석과 더 나은 디자인의 연구가 추가적으로 필요할 것으로 생각된다.

주요어: 방광암, survivin, 메타분석, 예후